Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor. [electronic resource]
Producer: 20180202Description: 171-180 p. digitalISSN:- 1557-3265
- Animals
- Antineoplastic Agents -- pharmacology
- Cell Line, Tumor
- Cell Survival -- drug effects
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Drug Evaluation, Preclinical
- Drug Synergism
- Gastrointestinal Stromal Tumors -- drug therapy
- Gene Expression Profiling
- Heterocyclic Compounds, 3-Ring -- pharmacology
- Humans
- Imatinib Mesylate -- pharmacology
- Mice
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-kit -- antagonists & inhibitors
- Signal Transduction
- Survival Analysis
- Tumor Burden -- drug effects
- Exome Sequencing
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.